Individualized Resting-State fMRI-**Guided Transcranial Magnetic** Stimulation Treatment for **Depressive Symptoms in Military Traumatic Brain Injury Patients**

2021 Amygdala Conference

David L. Brody, MD, PhD

Professor of Neurology, USU Director, Center for Neuroscience and Regenerative Medicine Traumatic Brain Injury Research Consortium and Clinical Collaborator, NINDS PI: Molecular Contrast MRI Unit Laboratory of Functional and Molecular Imaging






Objectives


- 1) To understand the relationship between depression, posttraumatic stress disorder, and traumatic brain injury in military service members injured in wartime.
- 2) To appreciate the role of individualized resting-state fMRI in guiding transcranial magnetic stimulation treatment for depressive symptoms in the context of traumatic brain injury

Washington University	Landstuhl Regional Medical Center	USUHS/HJF
Christine Mac Donald, PhD	LTC David Zonies, MD (2011-2014)	Xochitl Ceniceros PhD
Marcus Raichle, MD	LTC John Oh, MD (2010-2011)	Charline Simon MA
Josh Shimony, MD PhD	COL Raymond Fang, MD (2009 – 2010)	Lindsay Oberman, PhD
Avi Snyder, MD PhD	COL Stephen Flaherty, MD (2007-2009)	Diana Nora, BA
Matthew Parsons, MD	LTC John Witherow, MD (deceased)	Alex Koosman BA
Nicole Werner, PhD	Linda Wierzechowski ,RN	Tad Haight, PhD
Annie Johnson	Yolanda Barnes, RN	
Elliott Nelson, MD	Tess Stewart, RN	
&	Elizabeth Kassner, RN	
Shan Siddiqi, MD Nicholas Trapp, MD Pashtun Shahim MD PhD Carl Hacker, MD PhD Timothy Laumann MD PhD Sridhar Kandala, BS Xin Hong, BS Alexandre Carter, MD PhD Eric Leuthardt, MD	Kandahar Air Field – Camp Leatherneck, AFG LCDR Octavian Adam, MD CDR Dennis Rivet, MD John Ritter, MD Todd May, DO Maria Barefield OT Josh Duckworth, MD Donald LaBarge, MD Dean Asher, MD Benjamin Drinkwine, MD Yvette Woods, PhD	NIMH Lindsay Oberman, PhD Dzung Pham, PhD Yi-yu Chou Holly Lisanby, MD


Research studies of US Military Personnel with blastrelated and non-blast-related traumatic brain injury













Clinical outcomes in concussive blast-related vs non-blast TBI

- Prospective evaluation of patients with
 - blast + impact TBI (n=53),
 - non-blast related TBI (n=29),
 - blast-exposed controls evacuated for other reasons (n=27),
 - non-blast exposed controls (n=69)
- Objective: determine similarities and differences in clinical outcome between blast and non-blast TBI

McDonald et al., 2014 JAMA Neurology





Clinical outcomes in concussive blast vs nonblast TBI Multivariate correlates of clinical outcome Combat exposure intensity and PTSD Α 50 P =.002 P =.0001 40 CES Score 30-20

Exposed Controls	Exposed Controls		iblast BI	Blast Plus Impact TBI	
B 150 -		C		 Nonblast- Blast-exp Nonblast v Blast plus 	exposed con osed controls TBI impact TBI
Spearman r=0.3 P=.0003	5	150 00 100		Spearman r = 0. P = .30 (NS)	
CAS 100-000 000 000 000 000 000 000 000 000	° ° °	CAPS Total Score		2	


Variable	Estimate (95% CI)	P Value
Model 1 ^{a,b}		
Intercept	-0.9477 (-1.5376 to -0.3576)	.0016
MADRS	0.0689 (0.0199 to 0.1179)	.0059
No. of neuropsychological abnormalities	0.4381 (0.1173 to 0.7589)	.0074
MIDAS	0.02349 (0.00002 to 0.04696)	.0498
Model 2 ^c		
Intercept	-0.7573 (-1.3837 to -0.1309)	.0178
MADRS	0.0663 (0.0162 to 0.1163)	.0094
No. of neuropsychological abnormalities	0.4077 (0.0755 to 0.7399)	.0161
MIDAS	0.0182 (-0.0055 to 0.0418)	.1323
TBI vs control groups	-0.3546 (-0.7273 to 0.0182)	.0623
Nontgomery-Åsberg Depression Assessment; TBI, traumatic brain	Outcome Scale-Extended; MADRS, n Rating Scale; MIDAS, Migraine Disabil n injury. criterion was 202.5, and the likelihood	
Model 1 includes the GOS-E, M abnormalities, and MIDAS.	ADRS, number of neuropsychological	
Model 2 includes the GOS-E, M abnormalities, MIDAS, and TBI	IADRS, number of neuropsychological	


McDonald et al., 2014 JAMA Neurology


Clinical outcomes in concussive blast-related vs non-blast TBI


- Both TBI groups had higher rates of moderate to severe overall disability
- Self-reported combat exposure intensity was higher in the blast + impact TBI group than in the non-blast TBI group
- Global outcomes, headache severity, neuropsychological performance, and PTSD severity and depression were indistinguishable between the TBI groups
- One potential interpretation is that TBI itself is the driver of outcome, independent of injury mechanism or combat exposure intensity
- Headache severity and PTSD symptoms were worse in blast-exposed controls than non-blast exposed controls:
 - ongoing research is focused on effects of sub-concussive blast-exposures.
- Depression severity was the strongest correlate of overall clinical outcome, irrespective of mechanism of injury or other factors.


McDonald et al., 2014 JAMA Neurology





















6-12 month outcomes across multiple cohorts ... *the 2010 Directive Type Memorandum*


23














6-12 month outcomes after blast-related TBI


- Global disability was more common in those with TBI, those evacuated from theater, and those with **more severe depression and PTSD**.
- Disability was not significantly related to neuropsychological performance, age, education, self-reported sleep deprivation, injury mechanism, or date of enrollment.
- Imaging findings did not predict disability or specific outcomes.


Mac Donald et al, J Neurotrauma 2016












Acute (0-7d) predictors of 5 year outcome

- Blast TBI patients fared poorly at 5 yrs compared to controls on global disability, neurobehavioral impairment, and psychiatric symptoms, but not cognitive impairment
- Self-reported PTSD symptom severity (PCL-M) at 0–7 days is almost as good as a multivariate model for predicting 5 year outcomes.
- Recall that these were all service members who had prospectively diagnosed TBI and nearly all returned to duty within 28 days.
- Screening based on early PTSD symptoms would be a logical approach for future interventions designed to improve outcomes after blast-related TBI.

McDonald et al, JAMA Network 2019




ate to severe sleep impairment. Of interest, between the 1- and 5-year study evaluations, 18 combat-deployed controls (41%) and 40 patients with concussive blast TBI (80%) endorsed seeking assistance from a licensed mental health care professional, defined as a psychologist, psychiatrist, therapist, social worker, or other licensed, credentialed mental health care professional. Only 9 combat-deployed controls (20%) and 9 patients with concussive blast TBI (18%) reported that the mental health programs helped.


McDonald et al, JAMA Neurology 2017


37


Treatments for Depression and PTSD in the context of TBI


- Evidence-based psychotherapy: most likely similarly effective in TBI vs. non-TBI populations.
 - Challenges have been availability of appropriate therapists and commitment of patients to full courses of therapy.
- · Pharmacotherapy: relatively little evidence-based practice
 - RCTs of sertraline have not shown efficacy in the context of TBI
 - Methylphenidate may be effective in reducing PTSD symptoms in the context of TBI
- Transcranial Magnetic Stimulation:
 - Traditionally TBI was considered a contraindication due to seizure risk.
 - Recent appreciation that seizure risk is not significantly different from general population after concussion/"mild" TBI (>85% of military TBI, and 100% of our studies)





























		Active	Sham		
	Age (yrs)	43 ± 13	50 ± 18		
	Sex	7 M, 2 F	4 M, 2 F		
	Duration since TBI (yrs)	8.4 ± 8.2	8.1 ± 11.3		
	TBI mechanism	4/9 MVC 2/9 military/fire 1/9 sports 3/9 other	3/6 MVC 3/6 sports		
	Duration of depression (yrs)	4.8 ± 4.2	7.7 ± 9.9		
	Treatment trials (antidepressants, augmentation, or CBT)	4.8 ± 3.0	5.4 ± 3.4		
	Comorbid PTSD	4/9	3/6		
Siddiqi et a	Siddiqi et al. Journal of Neurotrauma 2019				















2 SITE TMS: A randomized, sham-controlled, blinded study of bilateral prefrontal individual connectome-targeted repetitive transcranial magnetic stimulation (ICTrTMS) to treat the symptoms of depression associated with concussive TBI

- PI: David Brody, MD, PhD
- Status: Study Closeout
- Total Enrolled: 10
- Start: June 28, 2019
- Projected End: October 27, 2020
- Study activities placed on hold due to COVID-19 restrictions as of March 2020. Study close out underway
- Key Study Team Members: Charline Simon, Dr. Lindsay Oberman, Diana Nora and Alexander Koosman ٠
- **Participating Sites:**
- Walter Reed National Military Medical Center
- Fort Belvoir Community Hospital







Brody lab and Collaborative Research Group

Washington University

Christine Mac Donald, PhD Marcus Raichle, MD Josh Shimony, MD PhD Avi Snyder, MD PhD Matthew Parsons, MD Nicole Werner, PhD Annie Johnson Elliott Nelson, MD &

Shan Siddiqi, MD

Nicholas Trapp, MD Pashtun Shahim MD PhD Carl Hacker, MD PhD Timothy Laumann MD PhD Sridhar Kandala, BS Xin Hong, BS Alexandre Carter, MD PhD Eric Leuthardt, MD Landstuhl Regional Medical Center LTC David Zonies, MD (2011-2014) LTC John Oh, MD (2010-2011) COL Raymond Fang, MD (2009 – 2010) COL Stephen Flaherty, MD (2007-2009) LTC John Witherow, MD (deceased) Linda Wierzechowski ,RN Yolanda Barnes, RN Tess Stewart, RN Elizabeth Kassner, RN

Kandahar Air Field – Camp Leatherneck, AFG

LCDR Octavian Adam, MD CDR Dennis Rivet, MD John Ritter, MD Todd May, DO Maria Barefield OT Josh Duckworth, MD Donald LaBarge, MD Dean Asher, MD Benjamin Drinkwine, MD Yvette Woods, PhD Michael Connor, PsyD

USUHS/HJF Xochitl Ceniceros PhD Charline Simon MA

Lindsay Oberman, PhD Diana Nora, BA Alex Koosman BA Tad Haight, PhD

NIMH

Lindsay Oberman, PhD Dzung Pham, PhD Yi-yu Chou Holly Lisanby, MD

